McKesson Corporation entered a definitive agreement with CD&R to acquire Option Care Health, Inc. for $32.05 per share, reflecting an approximately $5.8 billion total enterprise value. The transaction value represents an approximately 37% premium to Option Care Health’s closing share price on October 5, 2026.
Under the agreement, McKesson will invest approximately $1.4 billion for an approximately 49% minority interest; CD&R will hold an approximately 51% majority interest. The transaction is expected to close in the first half of calendar year 2027, subject to customary closing conditions, including Option Care Health stockholder approval and required regulatory approvals. The agreement also establishes a framework for McKesson’s future acquisition of CD&R’s interest, subject to specified conditions and regulatory approvals.
After closing, McKesson intends to account for its interest using the equity method, recording its share of Option Care Health’s net income or loss in Other Income, net. Option Care Health will remain a separate company led by its own management team and become privately held, with its common stock no longer publicly listed on Nasdaq upon completion. Option Care Health expects to release third-quarter results on November 4, 2026, and is withdrawing its previously disclosed financial guidance.
MCKESSON CORP (MCK) senior vice president, controller and chief accounting officer Napoleon B. Rutledge Jr. reported selling 111 shares of common stock on September 8, 2026 in an open-market or private transaction at a reported price of $891.45 per share. The transaction was carried out pursuant to a previously adopted trading plan dated March 2, 2026 in compliance with Rule 10b5-1(c), indicating it was pre-arranged. After this sale, he directly held 521 shares of McKesson common stock.
McKesson Corporation (MCK) reported that on August 25, 2026 it discovered a cybersecurity incident affecting its information systems. The investigation is in its early stages, and additional information and updates are being made available on the company’s website at www.mckesson.com/cybersecurity.
As of this report, McKesson states it has not determined that the incident is material or that it has had, or is reasonably likely to have, any material impact on the company, including its financial condition or results of operations.
Srinivasan Ramesh (NMN) reported acquisition or exercise transactions in this Form 4 filing.
McKesson Corp executive Ramesh Srinivasan, EVP and Chief Strategy Officer, received a grant of 368 Restricted Stock Units tied to common stock. These RSUs were awarded at a price of $0.00 per unit, bringing his directly held RSU balance from this grant to 368 units. The units are scheduled to vest in three equal installments on August 16, 2027, August 16, 2028, and August 16, 2029.
McKesson Corp director Bradley E. Lerman reported a sale of 301 shares of Common Stock on 2026-08-10 in a sale in open market or private transaction at $892.325 per share. Following this transaction, his reported direct holdings of McKesson common stock are 0 shares.
McKesson Corp reported initial equity holdings for EVP and Chief Strategy Officer Ramesh Srinivasan. He directly holds 11,959 shares of common stock. In addition, he holds several grants of restricted stock units (RSUs) convertible into common stock at an exercise price of $0.0000 per share.
The RSUs cover 2,486, 145, 557, 223 and 316 underlying common shares, each with specified vesting schedules extending between 2025 and 2029. The filing reflects holdings only, with no reported purchases, sales, or option exercises.
McKesson Corporation reported first‑quarter fiscal 2027 revenue of $105,380 million, up from $97,827 million a year earlier, with growth across all segments, especially Oncology & Multispecialty. Operating income increased to $1,319 million and consolidated net income to $1,032 million.
Net income attributable to McKesson fell to $614 million, or diluted earnings per share of $5.15, from $784 million and $6.25, reflecting substantially higher income allocated to noncontrolling interests and a $374 million redemption value adjustment on redeemable noncontrolling interests tied to recent oncology and Medical‑Surgical transactions. Operating cash flow was an outflow of $220 million, mainly from higher receivables and inventory, while cash and cash equivalents rose to $5,164 million.
Long‑term debt including current maturities increased to $9,729 million following new secured term loans at the Medical‑Surgical Solutions subsidiary, and McKesson maintained a $5,000 million undrawn corporate revolving facility. The company recorded $136 million of restructuring, impairment, and related charges and ended the quarter with $5,660 million of litigation liabilities associated with opioid‑related matters. Capital returns remained significant, with $2,530 million of share repurchases and $0.82 per‑share dividends in the quarter, and the quarterly dividend was raised to $0.94 per share in July 2026.
McKesson Corporation reported strong fiscal 2027 first‑quarter results with consolidated revenues of $105.4 billion, up 8% year over year, led by growth in the North American Pharmaceutical and Oncology & Multispecialty segments. GAAP diluted EPS was $5.15 versus $6.25, reflecting a $293 million redemption value adjustment tied to selling a 13% minority interest in Medical‑Surgical Solutions to Apollo Funds and other noncontrolling interest remeasurements.
Underlying performance was notably stronger on an adjusted basis. Adjusted Earnings per Diluted Share rose 20% to $9.93, driven by segment growth and a lower share count. The company returned $2.6 billion to shareholders, including $2.5 billion of share repurchases, and its board approved a 15% dividend increase to $0.94 per share, the tenth consecutive annual raise.
McKesson raised its fiscal 2027 outlook, guiding Adjusted EPS to $44.20–$45.00, implying 13%–15% growth, and continued advancing the planned separation of Medical‑Surgical Solutions, including a $1.25 billion minority sale, a $2.25 billion Term Loan B facility, and branding the future standalone business as Wellverse. Free cash flow was negative $372 million as operating cash outflows and investment exceeded inflows.
McKesson Corporation has a shareholder planning to sell common stock under Rule 144. The plan covers 7,925 common shares to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $6,683,192.44 as of the filing. These shares arise from multiple restricted stock vesting events recorded in May 2026 and classified as compensation from the issuer.